Home – Maiwald

我们在以上方面助您一臂之力

个性化的咨询和具有前瞻性的行动是奠定我们成功的基石。您尽可以信任我们一流的律师和专利律师团队，他们在知识产权保护领域的各个方面都富有经验。

关于业务领域的更多内容

保护

我们帮助您对您的知识产权进行保护与辩护，并在世界范围内专利组合的协调方面有着特别丰富的专业知识。

了解更多信息

诉讼

在专利侵权和专利有效性诉讼程序中，我们会竭诚为您提供支持。

了解更多信息

交易

我们从专利法的角度为您在合同谈判中出谋划策，并在企业并购交易过程中予以陪同。

了解更多信息

咨询

我们就专利申请策略为您提供咨询，评估自由实施（FTO）的相关问题以及专利权的有效性。

了解更多信息

News

11 Apr 2025

EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)

G 2/88 provides legal assessment for novelty of a non-medical use claim. G 2/88 allows acknowledging novelty of a non-medical use claim of an old compound for a particular pur...

8 Apr 2025

EPO revokes Roche’s Patent on combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer that was supported by results of Phase III AURELIA clinical trial

European Patent EP 2 825 558 concerns a combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer. The claim was supported by Phase III AURELIA c...

2 Apr 2025

Germany permits service of claims on Chinese defendants by publication, Managing IP, 2025

German courts now allow the service of claims on Chinese defendants by publication to ensure effective legal protection. The Regional Court of Frankfurt am Main confirmed this...

我们助您打造未来。

我们在以上方面助您一臂之力

保护

诉讼

交易

咨询

News

EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)

EPO revokes Roche’s Patent on combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer that was supported by results of Phase III AURELIA clinical trial

Germany permits service of claims on Chinese defendants by publication, Managing IP, 2025